Corporate Banner
Satellite Banner
Biologics & Bioprocessing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Insights into MRSA Epidemic

Published: Wednesday, May 02, 2012
Last Updated: Wednesday, May 02, 2012
Bookmark and Share
Scientists identify a gene playing a pivotal role in epidemic waves of MRSA infections in Asia.

NIH scientists and their colleagues in China have identified a gene that’s been playing a pivotal role in epidemic waves of methicillin-resistant Staphylococcus aureus (MRSA) infections in Asia. The finding suggests a potential target for novel therapeutics.

Decades ago, doctors used penicillin to treat people infected with the S. aureus bacterium, commonly known as staph. When S. aureus developed resistance to the antibiotic, doctors turned to methicillin.

In 1961, scientists identified the first strains of S. aureus bacteria that resisted methicillin. MRSA is now a leading cause of severe infections in hospitals.

Since bacteria inherit identical copies of their mother cell's genes, lineages are referred to as clones. MRSA epidemics occur in waves, with old clones of MRSA bacteria disappearing and new clones emerging.

A limited number of MRSA clones are responsible for most MRSA infections worldwide.

In China and large parts of Asia, ST239 is the predominant MRSA lineage. Recently, genome sequencing of ST239 revealed a rare new gene.

A research team led by Dr. Michael Otto of NIH's National Institute of Allergy and Infectious Diseases (NIAID) and Dr. Yuan Lu of Fudan University in Shanghai set out to study whether the new gene, which they called sasX, might play a role in the spread of MRSA in China.

The researchers analyzed 807 patient samples of invasive S. aureus taken over the past decade from 3 Chinese hospitals.

In the early online edition of Nature Medicine on April 22, 2012, they reported that sasX is more prevalent in MRSA strains from China than previously thought.

They found that the gene's frequency is also increasing: From 2003 to 2011, the percentage of MRSA samples containing sasX almost doubled, from 21% to 39%.

Most of the sasX-positive samples in the study were from ST239. However, while sasX was found almost exclusively among ST239 strains early in the study, its frequency among other clonal types increased considerably since then, from 5% in 2003-2005 to 28% in 2009-2011.

This supports a long-held theory that new clones of virulent MRSA arise through the exchange of DNA between different strains. Indeed, the sasX gene is embedded in a so-called mobile genetic element, a DNA segment that can transfer easily between strains.

The researchers next explored the biological role of sasX. They found that the protein coded by sasX appears at the S. aureus cell surface.

A series of laboratory and mouse studies showed that sasX helps the bacteria to colonize the nose and cause skin abscesses and lung disease. The protein also helps the bacteria evade human immune defenses.

Taken together, these findings establish sasX as a crucial factor in MRSA's virulence and a probable driving force of the Asian MRSA epidemic. “This research helps us understand how new, more dangerous forms of MRSA can keep appearing,” Otto says.

Based on their observations, the researchers predict that sasX is likely to continue to spread. They plan to keep monitoring its progress. They're also working to develop therapeutics against MRSA strains that express sasX.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More than 5,000+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Monkeys Protected by Zika DNA Vaccine
Experimental Zika virus DNA vaccines successfully protected monkeys against Zika infection.
Thursday, September 29, 2016
Mutations Linked to Immunotherapy Resistance
Researchers uncover mutations in tumors of three patients with advanced melanoma that allowed the tumors to become resistant to the immune checkpoint inhibitor pembrolizumab (Keytruda®).
Tuesday, August 09, 2016
Zika Vaccine Testing in Humans
The NAAID has initiated a clinical trail of a vaccine candidate for the prevention of the Zika virus infection.
Thursday, August 04, 2016
Zika Vaccine Candidates Show Promise
Two experimental vaccines have shown promise against a major viral strain responsible for the Brazilian Zika outbreak.
Friday, July 29, 2016
NIH Begins Yellow Fever Vaccine Trial
NIH has initiated an early-stage clinical trial of a vaccine to protect against yellow fever.
Thursday, July 28, 2016
Vaccine Strategy Targets Multiple Influenza Viruses
Scientists have identified vaccine-induced antibodies that can neutralize strains of influenza virus that infect humans.
Monday, July 25, 2016
NIH Investment Into HIV Research Expands
Funding has been awarded to six research teams to lead collaborative investigations worldwide toward an HIV cure.
Thursday, July 14, 2016
Large-scale HIV Vaccine Trial to Launch in South Africa
NIH-funded study will test safety, efficacy of vaccine regimen.
Wednesday, May 18, 2016
New HIV Vaccine Target Discovered
NIH-Led team have discovered a new vaccine target site on HIV.
Tuesday, May 17, 2016
Investigational Malaria Vaccine Protects Healthy U.S. Adults
Researchers at NIH have found that the malaria vaccine protected a small number of healthy, malaria-naïve adults in the U.S. from infection for more than one year after immunization.
Tuesday, May 10, 2016
Factors Influencing Influenza Vaccine Effectiveness Uncovered
The long-held approach to predicting seasonal influenza vaccine effectiveness may need to be revisited, new research suggests.
Thursday, April 21, 2016
Study Finds Factors That May Influence Influenza Vaccine Effectiveness
Researchers at NIH have suggested that the long-held approach to predicting seasonal influenza vaccine effectiveness may need to be revisited.
Wednesday, April 20, 2016
Improving Flu Vaccine Effectiveness
NIH study finds factors that may influence influenza vaccine effectiveness.
Wednesday, April 20, 2016
Submissions Open for the Cancer Moonshot Program
NCI opens online platform to submit ideas about research for Cancer Moonshot.
Tuesday, April 19, 2016
NIH Awards Grants to Explore Vaccine Adjuvants
NIH awards six grants to explore how combination adjuvants improve vaccines.
Wednesday, April 06, 2016
Scientific News
Mass Spec Technology Drives Innovation Across the Biopharma Workflow
With greater resolving power, analytical speed, and accuracy, new mass spectrometry technology and techniques are infiltrating the biopharmaceuticals workflow.
‘Cellbots’ Chase Down Cancer, Deliver Drugs Directly to Tumors
Programmable T cells shown to be versatile, precise, and powerful in lab studies.
Monkeys Protected by Zika DNA Vaccine
Experimental Zika virus DNA vaccines successfully protected monkeys against Zika infection.
New Weapon Against Hard-to-Treat Bacterial Infections
Using peptides, researchers have been able to prevent drug-resistance bacteria from forming abscesses.
Tapping Evolution to Improve Biotech Products
Researchers show how 'ancestral sequence reconstruction' can be used to guide engineering of a blood clotting protein.
Antibodies Paving the Way to HIV Vaccine
Researchers uncover factors responsible for the formation of broadly neutralizing HIV antibodies in humans.
Vaccine Against Common Cold Achievable
Researchers suggest that a vaccine against rhinoviruses is possible using variant virus vaccines.
Treating Sepsis with Marine Mitochondria
Mitochondrial alternative oxidase from a marine animal combats bacterial sepsis.
Biomolecular Manufacturing ‘On-the-Go’
Wyss Institute team unveils a low-cost, portable method to manufacture biomolecules for a wide range of vaccines, other therapies as well as diagnostics.
Molecular Switch Aids Immune Therapy
Researchers identify strategy to maximise effectiveness of immune therapy through molecular switch controlling immune suppression.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,000+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!